Xenon Pharma (XENE)
Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the discovery, development, and delivery of therapeutics to treat patie...
- Open
- 63.130
- High
- 63.775
- Low
- 61.850
- Prev. Close
- 63.790
- Volume
- 586.83K
- Turnover
- 36.52M
- Avg Price
- 62.240
- Bid/Ask Ratio
- -72.41%
- Amplitude
- 3.02%
- 52wk High
- 72.660
- Volume Ratio
- 0.64
- Turnover Ratio
- 0.65%
Xenon Pharma Analyst Rating
View moreForecast & Rating
Aug 26, 2026Price forecast
$81.3031.27%
Forecast & RatingStrong buy
20analysts
- Strong buy85.00%
- Buy15.00%
- Hold0.00%
- Sell0.00%
- Strong sell0.00%
News
- Unusual Whales · 1 day ago, 03:02 PM
Xenon to Highlight Phase 3 X-TOLE2 Clinical Data and Rational Polytherapy Potential for Azetukalner at EEC 2026
- PUBT · Aug 13 at 03:42 PM
Xenon Pharmaceuticals director Steven Gannon disposes of 10,000 common shares for $640,550
- Tip Ranks · Aug 7 at 05:55 PM
Xenon Therapeutics: Buy Rating Reiterated as AZK Progress and Strong Cash Position Support Compelling Risk-Reward; Price Target Maintained at $78
- Tip Ranks · Aug 7 at 06:10 AM
Xenon (XENE) Receives a Buy from RBC Capital
- Quartr · Aug 6 at 06:24 PM
XENE: Raised 2026 guidance on strong Atera demand, robust consumables growth, and margin expansion
- PUBT · Jul 31 at 03:01 PM
Xenon Pharma grants 32,758 inducement stock options, 19,013 RSUs to new hires
